Clinicopathologic parameters associated with the FDG-avidity in staging of early gastric cancer using $^{18}$F-FDG PET

Joon-Kee Yoon, MD, PhD, Cheulsu Byun, MD, Kyung Sook Jo, MD, Hun Hur, MD, PhD; Kee Myung Lee, MD, PhD, Seon Kyo Lim, MD, Dakeun Lee, MD, Su Jin Lee, MD, PhD, Young-Sil An, MD, PhD, Sang-Uk Han, MD, PhD

Abstract

This study investigated the clinicopathologic factors associated with $2\cdot[^{18}\text{F}]$fluoro-2-deoxy-$\text{D}$-glucose ($^{18}$F-FDG) uptake of early gastric cancer (EGC) and used them to design a clinical scoring method to predict FDG-avidity of EGC.

Two hundred twenty-nine retrospectively enrolled patients underwent preoperative $^{18}$F-FDG positron emission tomography/computed tomography (PET/CT). Histologic information was obtained by gastrectomy ($n = 195$) or endoscopic mucosal dissection ($n = 34$). The association between clinicopathologic factors and $^{18}$F-FDG uptake by the primary tumor was determined. The results were used to develop a clinical scoring method.

$^{18}$F-FDG uptake was detected in 49 (17.5%) patients. According to univariate analysis, location, gross type, World Health Organization classification, Lauren classification, size, depth of invasion, and lymphatic invasion were significant variables affecting $^{18}$F-FDG uptake ($P < .05$). According to multivariate analysis, location (lower 3rd, $P = .035$), gross type (0-I, 0-IIa, $P < .001$), size ($\geq 2.5\text{cm}$, $P = .026$), and depth of invasion (submucosa, $P = .007$) were significantly associated with FDG-avidity. A clinical scoring system, ranged from 0 to 4, was developed by giving one score to 4 independent variables. A cut-off value of 2.5 showed good prediction of FDG-avidity in EGCs, with a sensitivity and specificity of 65.0% and 85.2%, respectively.

$^{18}$F-FDG uptake by EGC depends on location, gross type, size, and depth of invasion of the primary tumor. A clinical scoring system based on clinicopathologic variables can predict the FDG-avidity of primary tumors in patients with EGC.

Abbreviations: AGC = advanced gastric cancer, EGC = early gastric cancer, ESD = endoscopic submucosal dissection, $^{18}$F-FDG = $2\cdot[^{18}\text{F}]$fluoro-2-deoxy-$\text{D}$-glucose, PET/CT = positron emission tomography/computed tomography, SUV$_{\text{max}}$ = maximum standardized uptake value.

Keywords: $^{18}$F-fluorodeoxyglucose, neoplasm staging, patient selection, positron-emission tomography, stomach neoplasms

1. Introduction

Early detection and therapeutic improvement over the past 2 decades have dramatically increased the 5-year survival rate of patients with stomach cancer (from 42.8% to 71.5%).\textsuperscript{[1]} Patients with early gastric cancer (EGC) without lymph node metastasis have an excellent prognosis, evidenced by a survival rate of 98% to 100%.\textsuperscript{[2]} EGC comprises about 50% to 60% of all gastric cancers in Asian countries, while the proportion of EGC is only 10% to 20% in Western countries. Such differences arise partly from the nation-wide cancer screening programs of Asian countries. Disagreement in histologic interpretation between Asian and Western countries also contributes to this discrepancy.\textsuperscript{[3]–[5]}

For the preoperative staging of stomach cancer, $2\cdot[^{18}\text{F}]$fluoro-2-deoxy-$\text{D}$-glucose ($^{18}$F-FDG) positron emission tomography/computed tomography (PET/CT) has a high sensitivity for detecting the primary tumor in patients with advanced gastric cancer (AGC). By World Health Organization (WHO) classification, the detection rate and $^{18}$F-FDG uptake is higher in tubular (intestinal) type than in poorly cohesive (diffuse) type. The low FDG uptake of signet ring cell type of poorly cohesive carcinoma is due to the reduced expression of glucose transporter-1. $^{18}$F-FDG PET/CT has a high specificity for detecting lymph node metastases.\textsuperscript{[6–10]}
The use of $^{18}$F-FDG PET/CT for EGC staging is not generally recommended because of its low sensitivity (25.9–50.3%).

However, extra-abdominal metastasis from gastric cancer is not uncommon, and even in EGC, distant metastasis to lymph node, liver, lung, or bone can be present.[5,11] $^{18}$F-FDG PET/CT, as a whole body imaging, is useful in the detection of distant metastasis both for intestinal and diffuse types.[7,12] Patients with EGC may benefit from $^{18}$F-FDG PET/CT in the detection of distant metastasis.

Although $^{18}$F-FDG uptake is tissue-specific and associated with tumor clinicopathologic factors, the nature of this relationship in EGC has yet to be determined.[10,13,14] Thus, in the present study, we retrospectively investigated the clinicopathologic factors of EGCs associated with FDG-avidity in the primary tumor during preoperative PET/CT. These factors were then used to develop a clinical scoring system to predict the FDG-avidity of EGC.

2. Materials and methods

2.1. Patients

The study patients were recruited retrospectively through a review of medical records acquired between June 2004 and July 2014. The 229 consecutive patients identified had undergone preoperative $^{18}$F-FDG PET/CT for a staging work-up after endoscopic diagnosis of EGC. Any patient with both EGC and AGC was excluded from the study to avoid a false-positive result. All patients underwent either gastrectomy with lymph node dissection (n = 195) or endoscopic submucosal dissection (ESD, n = 34).

Histopathologic information, including tumor size, location, gross type, WHO classification, Lauren classification, depth of invasion, lymphatic/venous/perineural invasion of the primary tumor, and lymph node staging, was collected retrospectively from each patient based on endoscopic or histologic reports. Lymph node staging was determined for those who underwent gastrectomy, based on the 8th edition of the staging manual of the American Joint Committee on Cancer.[13] The gross EGC type was determined according to the Macroscopic Classification of Early Gastric Cancer published by the Japanese Gastric Cancer Association[16,18].

All procedures were performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and the ethical standards of our Institutional Review Board on Human Experimentation (approval no. AJJR-MED-MDB-15). The requirement for obtaining informed consent from the patients was waived by the institutional review board.

2.2. $^{18}$F-FDG PET/CT acquisition

All patients fasted for at least 6 hours prior to the PET/CT examination. The blood glucose concentration was measured to ensure a level of <150 mg/dL. After intravenous injection of 370 MBq $^{18}$F-FDG, all patients were instructed to rest comfortably for 60 minutes. Immediately before PET, each patient drank a 500-mL bottle of water to flush out physiologic secretions within the gastric lumen.

Emission PET data were acquired from the skull base to the upper thigh using a PET/CT scanner (Discovery ST or Discovery STE, GE Healthcare, Milwaukee, WI). CT was performed without the administration of contrast material and using the following parameters: tube rotation rate 1 second/revolution, 120 kV, 60 mA, 7.5 mm/rotation, acquisition time 60.9 seconds, scan length 867 mm. PET data were reconstructed using non-contrast CT by iterative reconstruction (ordered-subsets expectation maximization with 2 iterations and 30 subsets, field of view = 600 mm, slice thickness=3.27 mm).

2.3. Image analysis

Two nuclear medicine physicians analyzed the PET/CT images, reaching a diagnosis based on consensus. Histologic information obtained before the PET/CT acquisition was blinded to the interpreters. Primary tumors with a higher $^{18}$F-FDG uptake than the rest of the gastric wall were considered FDG-avid. $^{18}$F-FDG confined to the gastric lumen was considered to be a physiologic secretion. For the semi-quantitative analysis of FDG-avid gastric tumors, volumes of interest were placed on attenuation-corrected transaxial PET images. The maximum standardized uptake value ($SUV_{max}$) was then calculated from the injected dose and the patient’s body weight.

For nine patients with multiple EGCSs, only the largest tumor was considered for analysis. In patients with 2 or more coexisting gross types of tumor, the type with the furthest spread was considered the representative gross type of that tumor.

2.4. Statistical analysis

All continuous values are presented as mean ± standard deviation. The Chi-squared test or Fisher exact test was used for the univariate analysis of $^{18}$F-FDG uptake with respect to the clinicopathologic variables. For variables with values of 0 in the cells of a 2 x 2 table, the median unbiased estimate was adopted as the odds ratio. The Mann–Whitney test was used for group comparisons with respect to a particular variable. Only those variables that were significant on univariate analysis were included in the binomial logistic regression analysis. A clinical scoring system was developed in accordance with previous reports.[17,18] Based on the multivariate analysis, one point was assigned to each independent factor. The optimal cut-off values for the clinical scores were determined by receiver operating characteristic curve analysis. All statistical analyses were performed using SPSS software (version 22.0; SPSS, Inc, Chicago, IL). A P-value <.05 was considered to indicate statistical significance.

3. Results

3.1. Patient characteristics

The mean interval from the PET/CT acquisition to treatment was 10 days (range, 0–60). The most common gastric location of the tumors was the lower 3rd of the stomach, with types 0-Ib and 0-IIc as the major gross types (77.8%, Table 1). The most common histologic type according to the WHO classification was tubular adenocarcinoma, followed by signet ring cell carcinoma. The average tumor size was 2.8 cm (median 2.5 cm). Among the 229 patients, 49 patients had FDG-avid gastric tumors. The majority of the patients had N0 disease; none had EGC with N3 lymph node metastasis. Neither PET/CT nor cytologic (or histologic) examination (omentum in 7, peritoneal fluid in 6, and ovary in 1 patient) found distant metastasis.

3.2. Univariate analysis of $^{18}$F-FDG uptake with respect to clinicopathologic factors in patients with EGC

According to univariate analyses, tumor location, gross type, WHO classification, Lauren classification, size, depth of invasion,
and lymphatic invasion were significantly associated with 18F-FDG uptake (Table 2). EGCs characterized by larger tumor sizes (≥2.5 cm, FDG-avidity 29.2%), submucosal invasion (26.7%), or lymphatic invasion (36.7%) had higher rates of FDG-avidity than did EGCs characterized by smaller tumor sizes (<2.5 cm, FDG-avidity 10.0%), mucosal invasion (7.3%), or no lymphatic invasion (12.2%). Tumors located in the lower 3rd of the stomach (FDG-avidity 23.8%) were more likely to show 18F-FDG uptake than were those in the middle 3rd (10.0%) or upper 3rd of the stomach. According to Stahl et al, AGCs in the proximal 3rd of the stomach are detected more frequently by 18F-FDG PET/CT.[20,22,23] For example, Han et al showed that gastric tumor size was positively related to the SUVmax (3.0 ± 0.4 for tumors <1 cm, 3.9 ± 2.1 for those 1–3 cm, and 5.7 ± 3.2 for those >3 cm). Other studies, however, did not find an effect of the primary tumor size on tumor detectability by 18F-FDG PET/CT.[10,24,25] Our study also showed a higher rate of FDG-avidity for tumors in the lower 3rd than those in the upper or middle 3rd of the stomach. According to Stahl et al, AGCs in the proximal 3rd of the stomach are detected more frequently by 18F-FDG PET/CT than are those in the distal 3rd (74% vs 41%) and are more likely to be of the intestinal growth type (65% vs 41%).[26] The Lauren classification has been consistently related to 18F-FDG uptake in gastric tumors, with a higher rate of FDG-avidity and a higher SUV for intestinal type tumors than for tumors of the non-intestinal type.[7,19,22-24,26] Our patients with intestinal type EGCs also had a higher rate of 18F-FDG uptake than did those with gastric tumors, with a higher rate of FDG-avidity and a higher SUV for intestinal type tumors than for tumors of the non-intestinal type.[7,19,22-24,26] The primary tumors of patients with a clinical score of 4 had a higher rate of 18F-FDG uptake (84.6%) (Table 4). The percentages of FDG-avidity in patients with clinical score 3, 2, and 1 were 36.1%, 15.6%, and 4.9%, respectively. Only 2 of 35 patients with clinical score 0 showed 18F-FDG uptake. This clinical scoring system performed well (area under the receiver operating characteristic curve, 0.801, P < .001) in predicting the FDG-avidity of EGC. Based on a cut-off value of 2.5, the clinical score had moderate sensitivity (65.0%) and high specificity (85.2%).

### 4. Discussion

The aim of our investigation was to evaluate a large number of patients with EGC to identify those likely to benefit from 18F-FDG PET/CT staging. Our clinical scoring system, developed using significant clinicopathologic predictors of FDG-avidity in EGC, showed modest sensitivity and high specificity in identifying these patients. To the best of our knowledge, this is the 1st study to evaluate this type of clinical scoring system in patients with EGC. Importantly, unlike previous reports that have analyzed both AGC and EGC together, only patients with EGC were enrolled in large numbers.

Previous reports demonstrated a relationship between tumor size and the detection rate of primary gastric cancers by 18F-FDG PET.[7,19-21] The tumors analyzed in those studies were divided into 2 or 3 categories, with larger tumors detected more readily than smaller tumors.[7,19,21] In addition, tumor size was shown to correlate not only with detectability but also with the SUV of the primary gastric cancer.[20,22,23] For example, Han et al showed that gastric tumor size was positively related to the SUVmax (3.0 ± 0.4 for tumors <1 cm, 3.9 ± 2.1 for those 1–3 cm, and 5.7 ± 3.2 for those >3 cm). Other studies, however, did not find an effect of the primary tumor size on tumor detectability by 18F-FDG PET/CT.[10,24,25]
with diffuse type EGCs (21.4% vs 6.1%, \( P = .016 \)). Furthermore, tumors in the lower 3rd of the stomach were more frequently of the intestinal type than were those in the upper or middle 3rd (56.6% vs 45.3%, \( P = .037 \)). Therefore, the higher detectability of tumors in the lower 3rd of the stomach may be attributed to the higher incidence of intestinal type tumors at this location.

Another finding of our study was that the depth of tumor invasion (submucosa) was an independent factor predicting high FDG PET/CT detectability. Although there are no published reports of a relationship between submucosal invasion of EGC and \(^{18}\)F-FDG uptake, AGCs were previously shown to be more easily visible than EGCs on \(^{18}\)F-FDG PET/CT.\cite{17,19,21,23,25} The pooled data from multiple studies revealed that the FDG-avidity of AGCs is much higher than that of EGCs, which, together with our data from patients with EGC, implies that the depth of tumor invasion is an important factor for FDG-avidity in gastric cancer.\cite{19}

This study is also the 1st to show that the endoscopic type of EGC is related to \(^{18}\)F-FDG uptake. Thus, types 0-I (83.3%) and 0-IIa (37.0%) had higher FDG-avidity than did other gross types (10.5%), which suggests that tumors expanding toward the gastric lumen take up more \(^{18}\)F-FDG than do those along the

### Table 2

| Factors                        | FDG (−) | FDG (+) | \( P \)-value | OR      | 95% CI     |
|-------------------------------|---------|---------|---------------|---------|------------|
| Age, yrs                      |         |         |               |         |            |
| \(< 61\)                      | 99 (86.1%) | 16 (13.9%) | .155         | 1.650   | 0.824–3.303 |
| \(\geq 61\)                   | 90 (78.9%) | 24 (21.1%) | <.001        |         |            |
| Sex                           |         |         |               |         |            |
| Female                        | 53 (80.3%) | 13 (19.7%) | .572         | 0.809   | 0.389–1.686 |
| Male                          | 136 (83.4%) | 27 (16.6%) | .027         |         |            |
| Location                      |         |         |               |         |            |
| Upper                         | 24 (88.9%) | 3 (11.1%) | .027         |         |            |
| Middle                        | 72 (90.0%) | 8 (10.0%) | <.001        |         |            |
| Lower                         | 93 (76.2%) | 29 (23.8%) | <.001        |         |            |
| Gross type                    |         |         |               |         |            |
| 0–I                           | 2 (16.7%) | 10 (83.3%) | <.001        |         |            |
| 0–IIa                         | 17 (63.0%) | 10 (37.0%) | <.001        |         |            |
| 0–IIb                         | 71 (91.0%) | 7 (9.0%)  | <.001        |         |            |
| 0–IIc                         | 90 (90.0%) | 10 (10.0%) | <.001        |         |            |
| 0–III                         | 9 (75.5%)  | 3 (25.0%)  | <.001        |         |            |
| WHO classification            |         |         |               | .0027   |            |
| Papillary adenocarcinoma      | 0 (0.0%)  | 2 (100.0%) | <.001        |         |            |
| Tubular adenocarcinoma        | 133 (79.8%) | 34 (20.2%) | <.001        | 3.831   | 1.729–8.488 |
| Mucinous adenocarcinoma       | 1 (50.0%)  | 1 (50.0%)  | <.001        | 4.170   | 2.005–8.673 |
| Signet-ring cell carcinoma    | 50 (94.3%) | 3 (5.7%)   | <.001        |         |            |
| Carcinoma with lymphoid stroma| 4 (80.0%)  | 1 (20.0%)  | <.001        |         |            |
| Lauren classification         |         |         |               | .016    |            |
| Diffuse                       | 62 (93.9%) | 4 (6.1%)   | <.001        | 3.714   | 1.814–7.605 |
| Mixed                         | 5 (38.5%)  | 8 (61.5%)  | <.001        |         |            |
| Indeterminate                 | 5 (62.5%)  | 3 (37.5%)  | <.001        |         |            |
| Intestinal                    | 88 (76.6%) | 24 (21.4%) | <.001        |         |            |
| Tumor size, cm                |         |         |               | <.001   |            |
| \(< 2.5\)                     | 126 (90.0%) | 14 (10.0%) | <.001        | 3.831   | 1.729–8.488 |
| \(\geq 2.5\)                  | 88 (70.8%) | 26 (29.2%) | <.001        |         |            |
| Depth of invasion             |         |         |               | <.001   |            |
| pT1a                          | 101 (92.7%) | 8 (7.3%)   | <.001        |         |            |
| pT1b                          | 88 (73.3%) | 32 (26.7%) | <.001        | 4.170   | 2.005–8.673 |
| Lymphatic invasion            |         |         |               | <.001   |            |
| Absence                       | 158 (87.8%) | 22 (12.2%) | <.001        | 4.170   | 2.005–8.673 |
| Presence                      | 31 (63.3%)  | 18 (36.7%) | <.001        |         |            |
| Venous invasion               |         |         |               | .211†   |            |
| Absence                       | 186 (83.0%) | 38 (17.0%) | .211†        | 3.263   | 0.527–20.198 |
| Presence                      | 3 (60.0%)   | 2 (40.0%)  | .211†        |         |            |
| Perineural invasion           |         |         |               | .759‡   |            |
| Absence                       | 184 (82.1%) | 40 (17.9%) | .759‡        | 0.690   | 0–3.900    |
| Presence                      | 5 (100.0%)  | 0 (0.0%)   | .759‡        |         |            |
| Lymph node staging            |         |         |               | .161    |            |
| N0                            | 131 (81.9%) | 29 (18.1%) | .161         |         |            |
| N1–3b                         | 25 (68.6%)  | 10 (31.4%) | <.001        |         |            |

Cl = confidence interval, FDG = 2-[\(^{18}\)F]fluoro-2-deoxy-D-glucose, OR = odds ratio.

WHO classification was subdivided according to the differentiation in performing analysis.

* Fisher exact test.

† Median unbiased estimate.

‡ Median unbiased estimate.
Specific $^{18}$F-FDG uptake by tumors of a particular gross type can be explained by their relationship with the depth of invasion. Submucosal invasion of type 0-I or 0-IIa tumors was 84.3%, compared with 43.3% for types 0-IIb, 0-IIc, and 0-III tumors ($P < .001$).

The $^{18}$F-FDG PET/CT has low sensitivity for signet ring cell gastric carcinoma. The FDG-based detectability of this tumor ranges from 14.3% to 70.6%, which is significantly lower than that of non-signet ring cell carcinoma (52.9–100%) and is consistent with its significantly lower SUV$_{\text{max}}$. In our univariate analysis, non-signet ring cell carcinomas were more FDG-avid than were signet ring cell carcinomas, but this difference was not confirmed in the multivariate analysis.

Lymph node metastasis is not a feature of primary tumors, and related data were not obtainable from our patients with ESD. Nonetheless, a close relationship between lymph node status and
the FDG-avidity of primary tumors has been reported.\(^7\)\(^{-25}\) In a study of 27 patients with EGC, Mukai et al determined that 7 patients had FDG-positive tumors, including 2 patients with lymph node metastasis. In a series of 20 patients with FDG-negative EGC, no patient had lymph node metastasis.\(^7\) We found that among the 195 patients with surgically resected EGCs, 39 had FDG-positive tumors, of whom 10 (25.6%) also had lymph node metastasis, compared with 25 (16.0%) of 156 FDG-negative EGCs. Accurate assessment of lymph node status is crucial in treatment planning for EGC, because ESD is indicated for negative EGCs. Accurate assessment of lymph node status is crucial in treatment planning for EGC, because ESD is indicated in determining the most appropriate treatment in patients with EGC.

In the present study, the 4 significant variables identified in the multivariate analysis were used as indicators in a clinical scoring system, using a cut-off value of 2.5 (based on a score of 0–4). This scoring system was developed to select patients with EGC who will benefit from \(^{18}\)F-FDG PET/CT. Kaneko et al also developed a pretreatment PET-based scoring system for gastric cancer, but their weighted scores were obtained by transforming the odds ratios of the 4 significant variables to a logarithmic scale.\(^{19}\) In their system, large (>3.0 cm), glucose transporter 1-positive tumors resulted in high scores, even in patients with EGC. Despite differences in the patient population, the measured variables, and the scoring method, the accuracy of detecting FDG-avid gastric cancers (sensitivity/specificity = 85%/71%) was similar to that obtained by our own method.

There were several limitations to our study. First, it was retrospective in its design and involved patients from a single center, such that selection bias was unavoidable. Second, in general, \(^{18}\)F-FDG PET has a low rate of detection of EGC, which may explain why there were only 49 true-positive cases (17.5%). Nonetheless, the population analyzed in this study was larger than those in previous \(^{18}\)F-FDG PET-based investigations of EGC. Finally, using \(^{18}\)F-FDG PET, tumors with a small volume can be underestimated by partial volume averaging effects, which may affect the positivity rate of \(^{18}\)F-FDG PET. Therefore, the results and the scoring system of this investigation can be generally applied after being validated further in other populations.

In conclusion, among the many clinicopathologic factors evaluated in this study, the location, gross type, size, and depth of invasion of the primary tumor were independently related to \(^{18}\)F-FDG uptake in EGC. A clinical scoring system based on these variables was used to predict the FDG-avidity of EGC, with modest sensitivity and high specificity. Because \(^{18}\)F-FDG PET/CT is not routinely performed for EGC staging, our clinical scoring system may help clinicians identify those patients with EGC likely to benefit from this imaging modality, for instance, predicting the risk of lymph node metastasis.

Acknowledgments

The authors appreciate the statistical review of the study by Jung-Dong Lee and Professor Dae Ryong Kang.

Author contributions

Conceptualization: Joon-Kee Yoon, Kyung Sook, Sang-Uk Han. Funding acquisition: Joon-Kee Yoon, Sang-Uk Han. Investigation: Joon-Kee Yoon, Kyung Sook, Hun Hur, Su Jin Lee, Young-Sil An, Sang-Uk Han. Data curation: Cheulsu Byun, Seon Kyo Lim, Dakeun Lee, Su Jin Lee.

Table 3

| Table 3 | Multivariate analysis between \(^{2-}[^{18}\text{F}]\)fluoro-2-deoxy-\(\alpha\)-glucose uptake and clinicopathologic variables. |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Factor  | \(P\)-value  | Exp (B) | 95% CI                                      |
| Location| .005          | 1.941  | 1.948–3.593                                |
| Gross type| <.001 | 0.444  | 0.294–0.672                                |
| WHO classification | .078 | 0.803  | 0.629–1.025                                |
| Tumor size | .026 | 2.527  | 1.117–5.716                                |
| Depth of invasion | .007 | 3.481  | 1.398–8.669                                |

CI = confidence interval, FDG = \(^{2-}[^{18}\text{F}]\)fluoro-2-deoxy-\(\alpha\)-glucose, WHO = World Health Organization.

Table 4

| Table 4 | Clinical scores and \(^{2-}[^{18}\text{F}]\)fluoro-2-deoxy-\(\alpha\)-glucose avidity. |
|---------|----------------------------------------------------------------------------------|
| score   | Location  | Clinicopathologic variables | Size | DOI | No. of patients | FDG-avidity, % |
| 4       | Lower     | 0-I, 0-IIa               | ≥2.5 | Submucosa | 13 | 84.6 |
| 3       | Lower     | 0-Ib, 0-Ilic, 0-II      | ≥2.5 | Submucosa | 23 | 34.8 |
| 3       | Lower     | 0-I, 0-IIa               | ≥2.5 | Submucosa | 6  | 33.3 |
| 3       | Lower     | 0-I, 0-IIa               | <2.5 | Submucosa | 1  | 100.0 |
| 2       | Lower     | 0-Ib, 0-Ilic, 0-II      | <2.5 | Submucosa | 19 | 21.1 |
| 2       | Upper, mid| 0-Ib, 0-Ilic, 0-II      | ≥2.5 | Mucosa    | 17 | 5.9  |
| 2       | Upper, mid| 0-I, 0-IIa               | <2.5 | Submucosa | 16 | 12.5 |
| 2       | Upper, mid| 0-I, 0-IIa               | ≥2.5 | Mucosa    | 8  | 25.0 |
| 2       | Lower     | 0-I, 0-IIa               | <2.5 | Mucosa    | 2  | 50.0 |
| 1       | Lower     | 0-Ib, 0-Ilic, 0-II      | <2.5 | Mucosa    | 2  | 0.0  |
| 1       | Upper, mid| 0-Ib, 0-Ilic, 0-II      | <2.5 | Submucosa | 41 | 4.9  |
| 1       | Upper, mid| 0-Ib, 0-Ilic, 0-II      | ≥2.5 | Mucosa    | 29 | 3.4  |
| 1       | Upper, mid| 0-I, 0-IIa               | <2.5 | Mucosa    | 10 | 0.0  |
| 0       | Upper, mid| 0-Ib, 0-Ilic, 0-II      | ≥2.5 | Mucosa    | 1  | 100.0 |
| 0       | Upper, mid| 0-I, 0-IIa               | <2.5 | Mucosa    | 35 | 5.7  |

DOI = depth of invasion, FDG = \(^{2-}[^{18}\text{F}]\)fluoro-2-deoxy-\(\alpha\)-glucose.
Formal analysis: Cheulsu Byun, Kyung Sook, Dakeun Lee, Young-Sil An.

Resources: Hun Hur, Kee Myung Lee, Seon Kyo Lim, Dakeun Lee.

Supervision: Kee Myung Lee, Sang-Uk Han.

Visualization: Dakeun Lee.

Writing – original draft: Joon-Kee Yoon, Cheulsu Byun, Kyung Sook.

Writing – review & editing: Sang-Uk Han.

References

[1] Jung KW, Won YJ, Hong SW, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127–41.

[2] Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355–61.

[3] Montgomery M, Fukuhara S, Karpeh M, et al. Evidence-based review of the management of early gastric cancer. Gastroenterol Rep (Oxf) 2013;1:105–12.

[4] Bausys R, Bausys A, Vysniauskaite I, et al. Risk factors for lymph node metastasis in early gastric cancer patients: report from Eastern European country-Lithuania. BMC Surg 2017;17:108.

[5] Gurusu S, Jung I, Kadar Z. Aberrant metastatic behavior and particular features of early gastric cancer. APMIS 2015;123:999–1006.

[6] Yun M, Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005;46:1582–8.

[7] Mukai K, Ishida Y, Okajima K, et al. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9:192–6.

[8] Yoon NR, Park JM, Jung HS, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in evaluation of gastric cancer stage. Korean J Gastroenterol 2012;59:347–53.

[9] Alakus H, Batur M, Schmidt M, et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 2010;31:532–8.

[10] Kim HW, Won KS, Song BI, et al. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging 2015;49:135–42.

[11] Sarela AI, Yelluri S. Leeds Upper Gastrointestinal Cancer Multidisciplinary Team Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg 2007;142:143–9.

[12] Kawanaka Y, Kiraizumi K, Fukushima K, et al. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT. Eur J Radiol 2016;85:989–95.

[13] Kaida H, Hiromatsu Y, Kurata S, et al. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer. Nucl Med Commun 2011;32:690–8.

[14] Jo I, Zeon SK, Kim SH, et al. Correlation of primary tumor FDG uptake with clinicopathologic prognostic factors in invasive ductal carcinoma of the breast. Nucl Med Mol Imaging 2015;49:19–25.

[15] Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.

[16] Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101–12.

[17] Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:18–21.

[18] Tseng JR, Chen KY, Lee MH, et al. Potential usefulness of FDG PET/CT in patients with sepsis of unknown origin. PLoS One 2013;8:e66132.

[19] Kaneko Y, Murray WK, Link E, et al. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med 2015;56:523–9.

[20] Yin C, Nan Y, Lu T, et al. Clinicopathological parameters influence assessment of FDG SPECT in gastric cancer. Hepatogastroenterology 2015;62:762–5.

[21] Yamada A, Oguchi K, Fukushima M, et al. Evaluation of 2-deoxy-2-[18F]fluorodeoxyglucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006;20:597–604.

[22] Kim JS, Young Park S. (18)F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value. Asia Ocean J Nucl Med Biol 2014;2:12–8.

[23] Han E-J, Choi W-H, Chung Y-A, et al. Comparison between FDG uptake and clinicopathologic and immunohistochemical parameters in preoperative PET/CT scan of primary gastric carcinoma. Nucl Med Mol Imaging 2009;43:26–34.

[24] Oh SY, Cheon GJ, Kim YC, et al. Detectability of T-Measurable diseases in advanced gastric cancer on FDG PET-CT. Nucl Med Mol Imaging 2012;46:261–8.

[25] Namikawa T, Okabayashi T, Nogami M, et al. Assessment of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. Int J Clin Oncol 2014;19:649–53.

[26] Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288–95.

[27] Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016;28:3–15.